GlobeNewswire

Mandalay Resources Corporation Announces Production and Sales Results for the First Quarter 2018

Dela

TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) announced today its production and sales results for the first quarter of 2018.

In the first quarter of 2018, Mandalay produced a consolidated 23,172 saleable ounces of gold equivalent and sold 29,151 ounces of gold equivalent.

Mark Sander, President and Chief Executive Officer of Mandalay, commented, "Mandalay's production and sales results for the first quarter of 2018 place us firmly on track to reach our 2018 production guidance of 101,000 to 113,000 gold equivalent ounces."

Dr. Sander continued, "Björkdal produced 12,716 ounces of gold in the first quarter of 2018, about 20% higher than the comparative year-ago quarter. Also in the current quarter, Björkdal recorded the second highest sales under Mandalay ownership at 17,677 gold ounces. This occurred as inventory from the record fourth quarter 2017 production was sold. Follow-on revenue due to the high sales volume in the first quarter will strengthen our cash position."

Dr. Sander concluded, "Costerfield produced 10,456 gold equivalent ounces in the first quarter of 2018. First quarter production was comparatively lower than in the previous year quarter due to expected lower mining grades.  We are on track with respect to the capital development program, announced in November 2017, to reach the Brunswick Lode, which we expect will open up additional production fronts and extend mine life. Simultaneously, we are aggressively continuing infill and extensional drilling in the recently announced Youle vein target, for which we released some very encouraging high-grade intercepts earlier this April (see Mandalay April 3, 2018 press release)."

Saleable production for the three months ended March 31, 2018:

  • The Company produced a total of 19,303 ounces of gold and 605 tonnes of antimony, representing a total of 23,172 ounces of gold equivalent in the first quarter of 2018, versus 21,370 ounces of gold, 741 tonnes of antimony and 435,076 ounces of silver, representing a total of 32,481 ounces of gold equivalent in the first quarter of 2017 when Cerro Bayo was operating. 
     
  • The Björkdal mine (Sweden) produced 12,716 ounces of gold in the first quarter of 2018, as compared to 10,648 ounces of gold in the first quarter of 2017.
     
  • The Costerfield mine (Australia) produced 6,587 ounces of gold and 605 tonnes of antimony in the first quarter of 2018, versus 7,987 ounces of gold and 741 tonnes of antimony in the first quarter of 2017. 
     
  • The Cerro Bayo mine (Chile) produced no metal in the first quarter of 2018 because it remains on care and maintenance due to the inundation event of June 2017. By comparison, in the previous year first quarter, it produced 435,076 ounces of silver and 2,735 ounces of gold.

Table 1 - Saleable Production for the First Quarter 2018 and 2017, and Fourth Quarter 2017

Metal Source Three months
ended 

31 March
2018
Three months
ended 

31 March
2017
Three months
ended

31 December
2017
Gold (oz) Björkdal 12,716 10,648 22,035
  Costerfield 6,587 7,987 7,222
  Cerro Bayo - 2,735 -
  Total 19,303 21,370 29,257
Antimony (t) Costerfield 605 741 805
Silver (oz) Cerro Bayo - 435,076 -
Average quarterly prices:        
Gold US$/oz   1,329 1,217 1,275
Antimony US$/t   8,499 8,058 8,137
Silver US$/oz   16.77 17.36 16.71
Au Eq. (oz)1 Björkdal 12,716   10,648 22,035
  Costerfield 10,456 12,891  12,360
  Cerro Bayo - 8,942 -
  Total 23,172 32,481 34,395

1  Quarterly gold equivalent ounces ("Au Eq. oz") produced is calculated by multiplying the saleable quantities of gold ("Au"), silver ("Ag"), and antimony ("Sb") in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au in the period.  Average Au price in the period is calculated as the average of the daily LME PM fixes in the period, with price on weekend days and holidays taken of the last business day; average Sb price in the period is calculated as the average of the daily average of the high and low Rotterdam warehouse prices for all days in the period, with price on weekend days and holidays taken from the last business day; average Ag price in the period is calculated as the average of the daily London Broker's silver spot price for all days in the period, with price on weekend days and holidays taken from the last business day. The source for all prices is www.metalbulletin.com.

Sales for the three months ended March 31, 2018:

  • The Company sold 24,808 ounces of gold and 679 tonnes of antimony, representing a total of 29,151 ounces of gold equivalent in the first quarter of 2018, versus 23,668 ounces of gold, 708 tonnes of antimony, and 451,777 ounces of silver, representing a total of 34,801 ounces of gold equivalent in the first quarter of 2017 when Cerro Bayo was operating.
     
  • Björkdal sold 17,677 ounces of gold in the first quarter of 2018, versus 13,121 ounces of gold in the first quarter of 2017.
     
  • Costerfield sold 7,131 ounces of gold and 679 tonnes of antimony in the first quarter of 2018, versus 7,547 ounces of gold and 708 tonnes of antimony in the first quarter of 2017.
     
  • Cerro Bayo sold nothing in the first quarter of 2018, as production has been suspended since June 2017.

Table 2 - Sales for the First Quarter 2018 and 2017, and Fourth Quarter 2017

Metal Source Three months
ended 

31 March
2018
Three months
ended 

31 March
2017
Three months
ended

31 December
2017
Gold (oz) Björkdal 17,677 13,121 18,565
  Costerfield 7,131 7,547 6,337
  Cerro Bayo - 3,000 142
  Total 24,808 23,668 25,044
Antimony (t) Costerfield 679 708 668
Silver (oz) Cerro Bayo - 451,777 18,334
Average quarterly prices:        
Gold US$/oz   1,329 1,217 1,275
Antimony US$/t   8,499 8,058 8,137
Silver US$/oz   16.77 17.36 16.71
Au Eq. (oz)1 Björkdal 17,677 13,121 18,565
  Costerfield 11,474 12,235  10,599
  Cerro Bayo - 9,445 383
  Total 29,151 34,801 29,547

1 Quarterly Au Eq. oz sold is calculated by multiplying the saleable quantities of Au, Ag, and Sb in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au for the period. The source for all prices is www.metalbulletin.com with price on weekend days and holidays taken of the last business day.

For Further Information:

Mark Sander
President and Chief Executive Officer

Greg DiTomaso
Director of Investor Relations

Contact: 
647.260.1566

About Mandalay Resources Corporation:

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in production gold, copper, silver and antimony projects in Australia, the Americas and Europe to generate near-term cash flow and shareholder value.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements regarding the Company's production of gold, silver and antimony for the 2018 fiscal year. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading "Risk Factors" in Mandalay's annual information form dated March 29, 2018, a copy of which is available under Mandalay's profile at www.sedar.com. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mandalay Resources Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum